

1 ~~30~~ Claim 50 (currently amended): A method in accordance with claim ~~claims 30 or~~
2 ~~32~~ in which said D, α tocopherol is present in the form of a member selected from the group
3 consisting of D, α tocopherol succinate, D, α -tocopherol nicotinate, D, α -tocopherol picolinate,
4 D, α tocopherol acetate, and tocotrienol.

1 Claim 51 (currently amended): A method in accordance with claim ~~claims 40 or~~
2 50 in which said tocotrienol is present in the form of a member selected from the group
3 consisting of tocotrienol succinate, tocotrienol nicotinate, tocotrienol picolinate, and tocotrienol
4 acetate.

1 Claim 52 (original): A method in accordance with claim 36 in which said
2 chromium is in the form of a member selected from the group consisting of chromium
3 dinicotinate, and chromium tripicolinate.

1 Claim 53 (currently amended): A method for treating a patient who is undergoing
2 sulfonylurea therapy for the prevention, management, and clinical amelioration of insulin
3 resistance and type 2 diabetes and conditions giving rise thereto, to reduce undesirable
4 physiological side effects, and enhance the therapeutic effectiveness, of said sulfonylurea
5 therapy, said method comprising administering to said patient a unit dosage form comprising as
6 active ingredients:

- 7 (a) L-carnitine,
- 8 (b) Ascorbic acid,
- 9 (c) Choline,
- 10 (d) ~~(e)~~ Taurine,
- 11 (e) ~~(f)~~ Folic Acid, and
- 12 (f) ~~(g)~~ Magnesium.

1 Claim 54 (original): A method in accordance with claim 53 in which said active
2 ingredients are formulated as a substantially homogeneous tablet or capsule that releases all of
3 said active ingredients into the stomach upon ingestion for contact with gastric fluid.